Group 1 - The core viewpoint of the article is that He Yuan Bio has successfully made its drug, Aofumin®, available in several top-tier hospitals in Hubei Province, including Wuhan University Zhongnan Hospital and Hubei Provincial People's Hospital [2] - The company emphasizes that the pricing of the drug adheres strictly to the national pricing policy, with specific prices to be confirmed based on public announcements from each hospital [2]

Core Viewpoint - The keyword for the stock market in 2025 is expected to be "innovative drugs," with significant stock price increases driven by the potential of in-development innovative drugs and BD (business development) transactions rather than traditional revenue from already marketed drugs [1] Group 1: BD Transactions - In 2025, China's innovative drug BD transaction total exceeded $100 billion, with notable orders reaching $10 billion, and upfront payments from multinational pharmaceutical companies reaching a new high of $1.25 billion [1] - Landmark transactions include a $13 billion collaboration between Qihuang Dejian and Biohaven/AimedBio in January, marking a milestone for China's ADC technology [2] - In May, 3SBio's deal with Pfizer exceeded $6 billion, setting a record for upfront payments in China at $1.25 billion, highlighting the value of both first-in-class and fast-follow drugs [2] - In July, a $12 billion strategic partnership between Hengrui Medicine and GlaxoSmithKline showcased the depth of early-stage pipelines in leading Chinese pharmaceutical companies [2] - In October, Innovent Biologics and Takeda's collaboration worth $11.4 billion included a cost-sharing model for global R&D, enhancing operational capabilities for future international ventures [2] Group 2: Milestone Payments and Emerging Fields - Several past BD transactions reached milestone payments in 2025, including a $300 million payment to China National Pharmaceutical's subsidiary from Merck and a $250 million payment to Bairui Tianheng from Bristol-Myers Squibb [3] - The focus of BD transactions is shifting from oncology to other therapeutic areas, with autoimmune diseases, metabolism, and central nervous system disorders emerging as new hot fields [3] - Notable deals include the global rights licensing of BTK inhibitor Orelabrutinib for multiple sclerosis by Nocera Biopharma, with a potential total transaction value exceeding $2 billion [3] - The metabolic field is gaining traction, driven by global weight loss trends, with several companies entering into licensing agreements for GLP-1 targeted drugs [3] Group 3: Independent Clinical Trials and Regulatory Approvals - Numerous innovative drug companies in China are advancing their own overseas clinical trials, achieving significant progress [4] - In early 2025, Dize Pharmaceutical's lung cancer targeted drug received priority review from the FDA and was approved in July, becoming the first globally innovative drug independently developed in China to gain approval in the U.S. [4] - Other advancements include breakthrough therapy designations for CS0159 by Kexi Kedi and a Phase III trial approval for a recombinant human albumin injection by Heyuan Biopharma [4] - These developments indicate that the Chinese innovative drug industry is becoming a significant force in global innovation, transitioning from fast-following to original innovation and integrating deeply into the global value chain [4]

Core Viewpoint - He Yuan Bio is at a critical stage of transitioning from technological breakthroughs to market penetration, focusing on accelerating the market access and sales volume of its product, Aofumin, while striving for profitability and establishing a positive cycle between R&D and commercialization [1] Group 1: Market Opportunity - The company aims to target the domestic replacement market for human serum albumin, which has a significant demand of approximately 1,000 tons annually in China, with 60%-70% of this demand currently relying on imports [2] - Achieving import substitution could represent a potential market space of over 20 billion yuan for the company [2] Group 2: Technological Advancements - The company has developed a recombinant protein high-efficiency expression platform that can achieve expression levels of 30g/kg, with a patented protein purification platform that can reach a purity of 99.9999% [2] - The company is also working on a new production line with an annual capacity of 120 tons of recombinant human albumin, expected to be completed by 2026, which will further reduce production costs and enhance competitiveness [3] Group 3: Commercialization Challenges - Despite having a leading technology and clear market potential, the company faces significant challenges in commercializing Aofumin, particularly in gaining access to national health insurance and hospital entry [5][9] - The company has established a professional sales team to promote the product and has signed agreements with multiple distributors to facilitate nationwide sales [9] Group 4: Future Growth Strategy - The company is focusing on expanding the indications for Aofumin, currently approved only for treating low albumin levels in liver cirrhosis, by preparing for post-marketing clinical studies and pursuing international approvals [10][11] - The company has outlined a "two new, one big" strategy for new drug development, targeting new targets, new concepts, and large market varieties, to ensure a sustainable growth pipeline [13][15] Group 5: Capital Market Perspective - He Yuan Bio's listing under the fifth set of standards on the Sci-Tech Innovation Board symbolizes a shift in market valuation logic from solely profit-driven to a dual assessment of technological barriers and commercialization potential [15] - The company emphasizes the importance of achieving profitability to support R&D through its cash flow rather than relying solely on financing [15]

Core Viewpoint - He Yuan Bio (688765.SH), a pre-profit biopharmaceutical company listed on the STAR Market, is facing significant challenges including expanding losses, tight cash flow, uncertainties regarding the commercialization of its core products, and controversies over information disclosure, making it a typical case for observing the survival status of unprofitable STAR Market enterprises [1][7]. Group 1: Continuous Losses and Cash Flow Pressure - He Yuan Bio expects a net profit loss of between 143 million to 167 million yuan for 2025, with cumulative losses exceeding 480 million yuan over the past three years, bringing total losses over four years to over 600 million yuan [2][8]. - The company's main product, recombinant human albumin, accounts for about 80% of revenue, but its selling price has declined from 151.46 yuan per gram in 2022 to 112.69 yuan in the first half of 2025, leading to a continuous decrease in gross margin [2][8]. - The company has incurred over 60 million yuan in litigation-related expenses with Ventria Bioscience, further eroding profits, while cash flow from operating activities has been negative for years, with cash reserves plummeting from 388 million yuan in 2022 to 75 million yuan by September 2025 [2][8]. Group 2: Main Business and Cost Control Challenges - The company attributes its losses to its core product, Aofumin (recombinant human albumin injection), being in the market introduction phase and production ramp-up, yet R&D expenditures have reportedly decreased in 2024 [3][9]. - High professional service fees in management expenses due to litigation reflect challenges in cost control and risk management [3][9]. - The company purchased liability insurance for all directors and executives shortly after its IPO, indicating a self-warning about operational risks despite the relatively small amount of expenditure, raising market scrutiny over its financial discipline [3][9]. Group 3: Core Product Commercialization and Information Disclosure Concerns - The future of He Yuan Bio largely depends on the commercialization prospects of its core product HY1001, but revenue forecasts for 2026 to 2030 have been quietly reduced from 7.255 billion yuan to 5.470 billion yuan, a cut of nearly 1.8 billion yuan, without clear explanation in the prospectus [4][10]. - The product lacks commercial validation, having experienced serious adverse events during Phase I clinical trials, raising concerns about its market readiness [4][10]. - Discrepancies in information disclosure have led to doubts about the rigor and transparency of the company's forecasts, which could continue to affect investor confidence in a market increasingly focused on R&D progress and commercialization capabilities [4][10]. Group 4: Industry Reflection - The case of He Yuan Bio reflects the common predicament faced by many unprofitable STAR Market companies, which must balance expanding losses, tight cash flow, uncertainties in product commercialization, and regulatory compliance in information disclosure [5][11]. - While the STAR Market's fifth set of standards has opened financing avenues for hard tech companies, sustainable business models, robust financial controls, and transparent disclosures remain essential to meet market and investor expectations [5][11]. - For He Yuan Bio, accelerating the commercialization of its core products, improving cash flow, and rebuilding market trust are critical challenges that must be addressed [5][11].

Group 1 - The company, He Yuan Bio, stated that it will disclose the number of shareholders in its periodic reports as required by information disclosure regulations [1] - For inquiries regarding the number of shareholders at specific points in time, the company requires shareholders to provide proof of shareholding and valid identification to its email [1] - The company will verify the identity of shareholders before responding to such inquiries [1]

Group 1 - The company has indicated that its 120-ton recombinant human albumin production line is expected to be completed by 2026, with new capacity dependent on equipment debugging and approval from the drug regulatory authority [2] - The company's drug, Ofumin®, is anticipated to be approved for market entry in July 2025, with steady progress in hospital access and distribution channel development [2] - There is currently a supply-demand imbalance in the market, indicating a strong demand for the company's products [2]

Core Viewpoint - He Yuan Bio has successfully completed the listing of its drug Aofumin® (recombinant human albumin injection) in the procurement catalog across various provinces in China, and sales have begun nationwide [1] Group 1 - The company has confirmed that Aofumin® is now available for sale in all provinces following the completion of the procurement catalog listing [1] - He Yuan Bio has scheduled the disclosure of its 2025 annual report for April 28, 2026, indicating a commitment to transparency regarding its sales performance [1]

Core Viewpoint - He Yuan Bio has successfully completed the listing of its drug, Aofumin (recombinant human albumin injection), in the procurement catalog across various provinces in China, and sales have commenced nationwide [1] Group 1 - The company has responded to investor inquiries regarding the sales status of Aofumin, indicating that it is now available in multiple provinces [1] - Aofumin's sales performance will be detailed in the upcoming annual report, scheduled for release on April 28, 2026, covering the fiscal year 2025 [1]

Group 1 - The company forecasts a total profit loss of between -167 million to -143 million yuan for the year 2025, with a net profit attributable to the parent company also expected to be in the same range [3][4] - The expected net profit attributable to the parent company, after deducting non-recurring gains and losses, is projected to be between -191 million to -162 million yuan [4] - The anticipated operating revenue for 2025 is estimated to be between 45 million to 50 million yuan, representing a year-on-year increase of 78.46% to 98.29% [4] Group 2 - In the same period last year, the company reported a total profit loss of -151.37 million yuan and a net profit attributable to the parent company of -151.37 million yuan [6] - The net profit attributable to the parent company, after deducting non-recurring gains and losses, was -166.75 million yuan [6] - The operating revenue for the previous year was 25.22 million yuan [8] Group 3 - The increase in sales revenue is attributed to the market introduction of the product "Aofumin" (recombinant human albumin injection) [9] - The production line for the related product is currently in a ramp-up phase, with capacity expected to gradually increase [9] - The company continues to maintain high levels of investment in research and development [10]

Group 1 - The company, He Yuan Bio, announced an expected annual revenue for 2025 between 45 million to 50 million, representing a year-on-year increase of 78.46% to 98.29% [1] - The net profit attributable to the parent company is projected to be between -1.67 billion to -1.43 billion [1]